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Abstract
The selection of optimal pancreas donors is one of the key factors in determining the ultimate outcome of clinical islet
isolation. North American Islet Donor Score (NAIDS) allows for estimating the chance of the success of islet isolation. It was
developed based on the data from over 1000 donors from 11 islet isolation centers and validated in the University of Alberta,
Edmonton, on the cohort from the most active islet transplant center. Now we aimed to also validate it in our much less active
program. Areas under the receiver operating characteristic curves (AUROCs) and logistic regression analyses were obtained
to test if NAIDS would better predict successful islet isolation (defined as post-purification islet yield >400,000 islet
equivalents (IEQ)) than previously described Edmonton islet donor score (IDS) and our modified version of IDS. We analyzed
the donor scores with reference to 82 of our islet isolation outcomes. The success rate increased proportionally as NAIDS
increased, from 0% success in NAIDS < 50 points to 40% success in NAIDS 80 points. AUROCs were 0.67 (95% confidence
interval (CI) 0.55–0.79) for NAIDS, 0.58 (95% CI 0.44–0.71) for modified IDS, and 0.51 (95% CI 0.37–0.65) for IDS and did not
differ significantly. However, based on logistic regression analyses, NAIDS was the only statistically significant predictor of
successful isolation (p ¼ 0.01). The main advantage of NAIDS is an enhanced ability to discriminate poor-quality donors than
previously used scoring systems at University of Chicago, with 0% chance for success when NAIDS was <50 as compared with
40% success rate for IDS <50. NAIDS was found to be the most useful available tool for donor pancreas selection in clinical
and research practice in our center, allowing for identification and rejection of poor-quality donors, saving time and resources.
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Introduction
Pancreatic islet transplantation (ITx) is a therapeutic option
for patients with “brittle” type 1 diabetes (T1DM) with the
potential to improve metabolic control and prevent hypogly-
cemia. Currently, most patients require subsequent islet infu-
sions to maintain long-term islet graft function and the
beneficial effect of procedure-improved glucose control.
The majority of patients (>90%) maintain at least partial islet
function for over 5 years, some for over 10 years1–3. Pan-
creatic islet mass, represented by islet equivalent (IEQ), is
the most important parameter that correlates with clinical
outcome after transplantation4. For this reason, it is the most
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important parameter in decision making for clinical islet
transplantation. The selection of an optimal pancreas donor
is one key factor in determining the ultimate outcome of
human islet isolation. To facilitate the selection of a suitable
organ, methods for the systematic, quantitative assessment
of donor quality have been developed for both pancreas
transplantation5,6 and ITx7,8. In 2005, based on their own
experience, the Edmonton group developed the Pancreas
Donor Scoring for the purpose of islet transplantation
(IDS)7. This model identified factors predictive of poor iso-
lation outcomes, including donor factors as well as the phys-
ical properties of the pancreas. IDS ranges between 0 and
100 points; the higher the score, the higher the chance for
islet isolation success. This success is defined as islet yield
>300,000 IEQ. Since then, the scoring system has been
adopted in many islet centers. At University of Chicago,
we first internally modified IDS by excluding factors related
to pancreas quality of preservation in order to enable early
decision making based only on donor-derived data, and to
avoid unnecessary organ procurement and shipment
(Table 1; data unpublished). Later, we developed and vali-
dated a new pancreas scoring system (NAIDS) based on data
from multiple islet centers8. We designed and conducted a
retrospective, multicenter analysis of data from 11 islet iso-
lation centers in North America. The data set from 1056
deceased donors was used for the development of the scoring
system to predict islet isolation success (defined as post-
purification islet yield >400,000 islet equivalents). Next,
NAIDS was validated on a cohort in the University of
Alberta, Edmonton. It is crucial that limitations and applic-
ability of assessment tools are recognized prior to their use in
clinical practice; therefore, this study aimed to validate
NAIDS externally, for use at our ITx program, which is
much less active than Edmonton. To assess the utility of
NAIDS we reviewed the outcomes of islet isolation proce-
dures performed at our institution with reference to donor
scores calculated according to IDS, our modification of IDS,
and NAIDS.
Materials and Methods
Study Design
The charts of all deceased donors of pancreatic islets were
retrospectively reviewed to assess their donor points accord-
ing to the previously described Edmonton IDS, our modifi-
cation of IDS, and NAIDS. The values of all islet donor
scores were analyzed with reference to post-purification islet
yield as expressed in IEQ. Successful islet isolation was
initially defined as post-purification islet yield greater than
400,000 IEQ. We also analyzed scenarios in which success-
ful isolation was considered either 350,000 IEQ or 300,000
IEQ. Cases other than successful islet isolation were labeled
Table 1. The University of Chicago modification of Islet Donor Score (IDS).
Criterion
Allocated
Points Variable Range and Associated Score
Assigned
Score-IDS
Age (years)
20
< 20 20-25 26-35 36-55 56-65 > 65
15 15 15 20 10 5
BMI (kg/m2)
15
< 20 20.1-25 25.1-30 30.1-35 > 35
5 10 12 15 12
Cold ischemia time
(hours)
15
< 3 3-8 8.1-12 > 12
12.5 15 10 5
Blood work levels*
5
blood work Abnormal Abnormal Both Abnormal
normal Specific
Biomarkers**
Other
Biomarkers***
Biomarkers
5 2 4 0
Medical history
5
Clean Cardiac arrests Alcohol abuse Arterial
Hypertension
5 -15 -3 -10
Hospital stay (days)
5
< 2 2-4 5-7 >8 Days
5 3 2 0
Vasopressors
5
None Single Double Triple or more
(# of drugs used) 5 3 0 -5
Cause of death
20
Anoxia/
Hypoxia
Trauma with
abdominal Injury
Trauma without
abdomial Injury
Cerebral Vascular
Event
0 8 10 20
Procuring team
10
Own Distant
10 5
Sum total (Score) 100 0
*Refer to local reference values
** Specific biomarkers are defined as blood glucose, amylase, lipase. Abnormal value in Illinois is Lipase >190U/L, Amylase >200 U/L and Glucose >200 mg/
dL(or >11.1 mmol/L)
*** Other biomarkers include AST, ALT, Creatinine, BUN. Abnormal value in Illinois is ALT >50IU/L, AST >40IU/L, Creatinine >1.38 mg/dL and BUN>24 mg/L.
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as failed islet isolation. All donor data were entered in RED-
Cap Project in the University of Chicago website before
analysis.
Donor Selection
We pre-selected only brain dead; HIV, HBV (HBsAg,
HBcAb) and HCV seronegative; NAT negative; and non
CDC high-risk donors according to Centers for Disease Con-
trol9 with HbA1c below 6. Next, the primary investigator, a
transplant surgeon, made a decision of acceptance or rejec-
tion based on modified IDS score, urgency of the transplant,
surgical comfort of procuring surgeon, and expected cold
ischemia time (CIT) below 12 h. Pancreata were then
shipped to the islet isolation facility for processing, in cold
(4C) preservation solution SPS1 (Organ Recovery System,
USA) or histidine-tryptophan-ketoglutarate (Köhler Chemie
GmbH, Germany).
Islet Isolation
Islets were isolated in a good manufacturing practice (GMP)
facility at the University of Chicago using the Ricordi stan-
dard semiautomated procedure10. Briefly, collagenase (Lib-
erase; Roche, Indianapolis, IN) solution was infused through
the main pancreatic duct, and the organ was digested in the
Ricordi Chamber (Biorep Technologies, Miami, FL). After
digestion, all tissue was collected, and islets were purified
with a continuous density gradient in the COBE 2991 Cell
Processor (Caridian BCT, Lakewood, CO). Islet yield was
determined by manual count of dithizone-stained samples,
converting the different islet sizes into IEQ11.
Islet Donor Scores
IDS. This continuous model consists of nine donor factors
(age, body mass index (BMI), cause of death, length of hos-
pital stay, amylase/lipase activity, use of vasopressors, blood
glucose, social and medical history), two transplant/procure-
ment factors (CIT and procurement team), and seven pan-
creas physical properties (size, quality of flush, consistency,
quality of procurement, damage, quality of packaging, fat
content). The combination of the donor quality, transplant/
procurement factors, and pancreas quality factors was given
a numerical score from 0 to 100 to determine the quality of a
pancreas for islet isolation. The higher the score, the higher
the chance for islet isolation success, defined as islet yield
>300,000 IEQ7.
Modified IDS. Our modification of the IDS model included
only eight donor factors and a single procurement factor
(Table 1). The pancreas quality factors were excluded to
allow actual organ selection before the procurement. The
range of donor points extends from 0 to 100 and as in IDS,
the higher the score, the higher the chance for islet isolation
success.
NAIDS. The NAIDS is a comprehensive scoring system. It
consists of donor variables that predict islet isolation success
with post-purification IEQ yielding over 400,000 out of a
total of 100 points. A higher NAIDS corresponds to a higher
success rate. Donor body surface area (BSA), BMI, and use
of vasopressors were recognized as main donor variables
included in the NAIDS. There were also two supplemental
composite factors—favorable (based on serum Na and glu-
cose, along with body weight (BW) and own organ-
procuring team), and unfavorable (based on age, CIT, BW,
serum HbA1c, liver enzymes, blood urea nitrogen (BUN)
and amylase). BSA is given a maximum of 25 points, fol-
lowed by BMI with 10 points. The absence of vasopressor
usage is awarded a maximum of 15 points. If there are no
unfavorable factors, 35 points are given. Favorable factors
are given a maximum of 15 points (Table 2)8.
Statistical Analysis
Descriptive statistics are expressed as mean + standard
deviation or median with interquartile range (IQR) as
appropriate. Data were tested for normality. Receiver oper-
ating characteristic curves were made for IDS, modified
IDS, and NAIDS values. The area under the receiver oper-
ating characteristic (AUROC) curves were compared
between the donor scores to determine which of the indices
detected the outcome (i.e., post-purification islet yield
>400,000 IEQ or >350,000 IEQ or 300,000 IEQ) with
greater discrimination. An AUROC  0.5 was considered
no discrimination, an AUROC between 0.7 and 0.8 was
considered acceptable, an AUROC between 0.8 and 0.9 was
considered excellent, and an AUROC > 0.9 was considered
outstanding. Univariate logistic regression analysis was
performed to identify the predictor of successful islet iso-
lation among the donor scores. A p value of less than 0.05
was considered statistically significant. The statistical anal-
yses were performed using Statistica 12 (StatSoft, Poland)
software.
Results
Donor Characteristics
The data set consisted of 82 consecutive human islet isola-
tion procedures performed at our institution between 2007
and 2011, 18 research-grade (to train new personnel and
optimize the conditions) and 64 clinical-grade isolations
(with the goal to transplant) (Table 6). Two research-grade
isolations were excluded from the analysis due to technical
failure and early termination of the cell processing.
The external validation cohort included a significantly
lower number of patients than both the derivation and
Edmonton validation cohorts. The average donor for this
cohort was similar to the reference donor described in the
NAIDS derivation model in terms of age, BMI, and gender,
but there were significantly more deaths due to head trauma
without abdominal injury. We also used pancreata procured
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by a distant team significantly more often. The donor demo-
graphics for this cohort and the cohort used to derive the
NAIDS are shown in Table 3.
Donors were grouped into five strata depending on the
total number of points achieved in each of the scoring sys-
tems. The distribution of results differed according to the
scoring model used; that is, less than 4% of University of
Chicago donors had 80 points in IDS, only 4.9% according
to modified IDS in comparison to 30.5% of donors with 80
points when NAIDS was calculated. Examination of NAID
scores showed that the organs utilized were similar between
derivation and original validation cohort, with 51.6% and
56.4% of pancreata from donors with NAIDS above 60
points in the derivation and original validation cohort,
respectively. However, analysis of NAIDS distribution in
our center’s cohort showed skewed scores, with few low-
score donors and a preponderance toward a higher propor-
tion of high NAID scores with 75.6% of scores above
60 points (Table 4).
Univariate Logistic Regression Analysis
Of the 82 analyzed cases, 25 (30.5%) were successful islet
isolations. This rate was similar to the NAIDS derivation
cohort, but lower than 50.5% (90/179) in the Edmonton
validation cohort. Logistic regression confirmed that
NAIDS was a statistical significant predictor of the isola-
tion success defined as 400,000 IEQ with odds ratio (OR)
of 1.05 (95% confidence interval (CI) 1.01–1.09) with p ¼
0.01, whereas IDS and modified IDS were not (p ¼ 0.83
and 0.26, respectively). When the cut-off for isolation suc-
cess was set as 350,000 and 300,000 IEQ the results were
similar with OR of 1.04 (95% CI 1.01–1.07) with p ¼ 0.01
and OR of 1.03 (95% CI 1.00–1.05) and p ¼ 0.03 for
NAIDS, respectively.
Success Rate Based on Various Donor Scores
The success rate increased proportionally as the NAIDS
increased, from 0% success in NAIDS < 50 points (0/13)
to 40.0% success (10/25) in NAID score  80 points. When
the NAIDS was between 50 and 80 points, the chance for
success was approximately 34% (15/44). Distribution of the
success rate depending on the NAIDS in the University of
Chicago cohort was similar to the distribution of the success
rate in the Edmonton and multicenter derivation cohorts
(Fig. 1). Distribution of the success rate for scores between
50 and 80 was similar for NAIDS and IDS. Similarly, when
the total number of points exceeded 70, the chance for islet
yield greater than 400 kIEQ was around 40% irrespective of
the scoring system used. However, when NAIDS was < 50
there was 0% chance for success, while when IDS was < 50
there was still 40% chance of success with the threshold set
at 400 kIEQ (p ¼ 0.02). With the total number of points
below 60, the difference in the number of successes between
NAIDS and IDS was of borderline significance (p ¼ 0.09).
We identified 32 isolations when the difference in scores,
assuming pancreas from the same donor, between NAIDS
and IDS was equal or greater than 19.5 points (e.g., NAIDS
84 points and IDS 64 points; NAIDS 47 points with IDS 81
points). These included 24 cases when NAIDS was greater
and eight cases when IDS was higher. When NAIDS was
greater than IDS then isolation success, defined as post-
purification islet yield greater than 400,000 IEQ, was
achieved in 11 out of 24 (46%) cases. In eight cases when
IDS was at least 19.5 points greater than NAIDS, there were
no successful isolations (p ¼ 0.029).
Validation of the NAIDS
For validation of the NAIDS, we plotted the receiver
operating characteristic curves using the multicenter deriva-
tion (n ¼ 1056) and the University of Chicago validation
Table 2. North American Islet Donor Score.
BSA X<1.54 1.54X<1.82 1.82X<2 2X<2.18 2.18X
0 5 10 20 25 pts
Vasopressor more than 2 double single none
0 3 10 15 pts
BMI X<20.1 20.1X<28.1 28.1X<32.5 32.5X<52.0 52.0X
0 2 7 10 0 pts
Unfavorable factors Age (y) < 20, > 75 ALT (U/L) > 1070 At least one None
CIT (h)  2, > 17 AST (U/L) > 580
Body weight (kg) < 55 BUN (mg/dL)  80
HbA1c (%) > 6.5 Amylase (U/L) > 1500 0 35 pts
Favorable factors Body weight (kg) > 120 None One Two More than 2
Own team procurement
130<Na (mEq/L)<160
Peak glucose (mg/dL)<410 0 2 7 15 pts
188 Cell Transplantation 28(2)
cohort data (n ¼ 82) (Figure 4). The AUROC for validation
cohort data for isolation success defined as post-purification
islet yield greater than 400,000 IEQ was 0.67 (95%
CI 0.551–0.79) (Table 5, Fig. 2), which was not significantly
different (p¼ 0.39) from that obtained from the development
cohort. Furthermore, a similar proportional increase in a
Table 3. Baseline Characteristics of the NAIDS Derivation (n¼ 1056) and External Validation (n¼ 82) Cohorts. (A) Continuous Variables,
(B) Categorical Variables.
(A)
Derivation cohort
University of Chicago validation
cohort
Mean + SD Range Mean + SD Range
Age (year) 45.8 + 13.2 5–77 43.0 + 13.6 1–71
Height (cm) 171.8 + 10.6 125–210 173.0 + 18.3 60–196
Body weight (kg) 85.6 + 21.3 25–200 97.9 + 26.1 8–180
Body mass index (kg/m2) 28.9 + 6.5 13.3–66.6 32.1 + 6.5 17.6–56.9
Body surface area (m2) 2.01 + 0.28 0.97–3.21 2.2 + 0.4 0.37–3.1
Cold ischemia time (h) 9.4 + 4.1 0.67–23.9 9.27 + 3.4 2.78–18.7
Amylase (U/L) 136 + 206 5–1953 125.7 + 172.4 10–999
Lipase (U/L) 78 + 125 3–1186 88.8 + 164.3 3–964
AST (U/L) 101 + 229 5–4092 178.9 + 390.3 16–2266
ALT (U/L) 81 + 181 4–3268 123.6 + 274.0 12–1984
HbA1c (%) 5.6 + 0.7 3.5–14.6 5.3 + 0.5 3.5–6.4
Peak glucose (mg/dl) 235 + 83 79–982 257.0 + 92.1 144–627
Lowest glucose (mg/dl) 119 + 36 15–311 108.2 + 27.7 17–221
BUN (mg/dl) 19 + 12 2–105 22.8 + 13.2 8–80
Creatinine (mg/dl) 1.6 + 2.5 0.3–75 1.65 + 1.02 0.6–6.7
Na (mEq/L) 150.7 + 9.8 125–189 157.0 + 10.2 136–194
(B)
Derivation cohort University of Chicago validation cohort
Variables n (%) n (%)
Gender
Male 586 (55.5) 54 (65.9)
Female 470 (44.5) 28 (34.1)
Cause of death
Cerebrovascular accident 590 (55.9) 42 (51.2)
Anoxia 136 (12.9) 6 (7.3)
Head trauma with abdominal injury 23 (2.2) 1 (1.2)
Head trauma without abdominal injury 304 (28.8) 32 (39)
Procurement team
Own 247 (23.4) 8 (9.8)
Distant 808 (76.6) 74 (90.2)
Hospital stay
<2 days 247 (23.4) 3 (3.7)
2–4 days 604 (57.2) 55 (67)
5–7 days 133 (12.6) 15 (18.3)
>7 days 64 (6.1) 9 (11)
Vasopressor use
None 152 (14.4) 9 (11)
Single 401 (38.0) 28 (34.1)
Double 278 (26.3) 34 (41.5)
Triple 153 (14.5) 11 (13.4)
More than three 47 (4.5) –
Medical history*
Alcohol abuse 152 (14.4) 17 (20.7)
Hypertension 362 (34.3) 36 (43.9)
Cardiac arrest 190 (18.0) 14 (17.1)
Absence of above three 479 (45.4) 29 (35.4)
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success rate was observed as the NAIDS increased in the
validation cohort (Fig. 3). AUROCs for modified IDS and
IDS were 0.58 (95% CI 0.44–0.71) and 0.51 (95% CI 0.37–
0.65), respectively. However, the difference between the
AUROCs for various scoring systems did not reach statistical
significance. The results were comparable when the threshold
for isolation success was set at either 350 kIEQ or 300 kIEQ.
Discussion
The outcome of human islet isolation depends on donor-,
pancreas-, and isolation-related variables12,13. Despite
improvements and standardization of isolation procedures,
the outcome of human islet isolation remains unpredictable
and highly variable. The most experienced centers are only
able to obtain a sufficient islet yield from 30–50% of isola-
tion procedures8. A careful selection of pancreata for pro-
cessing should allow higher transplant efficiencies.
Therefore, a reliable method of systematic, quantitative
assessment of donor quality is highly desired. Since its intro-
duction in 2005, IDS has been the mainstay of donor evalua-
tion for the isolation of pancreatic islets. Once the clinical
utility of a new donor score is established, internal and exter-
nal validation is required prior to the implementation into
clinical practice to assess the applicability in a particular
context. The objective of this single-center study was to
compare IDS, our modification of IDS, and recently intro-
duced NAIDS in our own medium-volume center in their
Table 5. The Areas Under Receiver Operating Curves (AUROC)
of the NAID, Modified ID, and ID Scores for the Detection of
Isolation Success (n ¼ 82).
Islet isolation success defined as total post-purification
IEQ > 400,000
AUROC 95% CI p value
NAIDS 0.67 (0.55–0.79) 0.005
modified IDS 0.58 (0.44–0.71) 0.26
IDS 0.51 (0.37–0.65) 0.92
Islet isolation success defined as total post-purification IEQ >
350,000
NAIDS 0.66 (0.54–0.78) 0.007
modified IDS 0.54 (0.41–0.67) 0.54
IDS 0.49 (0.36–0.62) 0.83
Islet isolation success defined as total post-purification IEQ >
300 000
NAIDS 0.62 (0.5–0.74) 0.05
modified IDS 0.54 (0.41–0.67) 0.57
IDS 0.5 (0.36–0.63) 0.94
AUROC: area under receiver operating curve; CI: confidence interval; IDS:
Islet Donor Score; NAIDS: North American Islet Donor Score
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Fig. 1. Distribution of the isolation success rate (post-purification
islet yield greater than 400,000 IEQ) depending on NAID score in
the multicenter derivation cohort (n ¼ 1056), Edmonton validation
cohort (n ¼ 179), and University of Chicago (n ¼ 82).
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Fig. 2. Distribution of the isolation success (postpurification islet
yield greater than 400,000 IEQ) rate according to various donor
scores (IDS, modified IDS and NAIDS) in University of Chicago
validation cohort (N ¼ 82).
Table 4. The Characteristics of Utilized Pancreata.
NAID score
Derivation
cohort
(n ¼ 1056)
Edmonton
validation cohort
(n ¼ 179)
University of
Chicago validation
cohort
(n ¼ 82)
x  80 12.3% 12.8% 30.5%
80 > x  70 19.4% 24% 30.5%
70 > x  60 19.9% 19.6% 14.6%
60 > x  50 25.3% 30.7% 8.5%
x < 50 23.1% 12.8% 15.9%
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ability to facilitate recognition of a suitable pancreas donor
among all reported donors.
NAIDS incorporates five criteria (including two compo-
site ones) for the estimation of pancreas weight and quality.
The rationale for the choice and arrangement of these
variables has been described in detail in the original NAIDS
development study8. Briefly, 50 out of a maximum of
100 points are assigned for BSA, BMI, and the number of
vasopressors used in the donor. BMI has long been shown by
many authors to positively correlate with islet isolation out-
come13–18. Recently, a positive association has also been
found between islet size, islet insulin content (normalized
for size), basal or stimulated insulin secretion, and BMI19.
However, on the other hand, Olehnik and colleagues
observed high inter-individual heterogeneity of beta-cell
mass, with no clinically significant correlation with BMI.
BMI is used as a clinical indicator of obesity, but it in fact
does not differentiate between adipose tissue and muscle
mass20. This could, at least in part, explain the inter-
individual heterogeneity of beta-cell mass irrespective of
BMI value. It is also possible that the composition of extra-
cellular matrix structure in obese donors favors liberating
islets from exocrine tissues and therefore results in a higher
islet yield, when the islet number is in fact similar or lower.
Kin et al. reported that BW and BSA were more strongly
correlated with pancreas weight21. To ensure a more accu-
rate estimation of isolation outcomes, NAIDS uses com-
bined variables of BSA, BMI, and BW, for which positive
correlation with pancreas size and islet yield were previously
described8,22. According to NAIDS, the lack of donor vaso-
pressor treatment predicts a favorable outcome. However,
conflicting results regarding the influence of vasopressor use
in donors on the isolation outcomes have been reported with
no effect4,18, elevated yield16, or reduced islet yield14. The
need for vasopressors reflects the cardiovascular status of the
multiorgan donor with unsatisfactory tissue perfusion and
progressive organ damage, including the pancreas. Ischemia
of the pancreatic tissue leads to more extensive islet cell
damage or death prior to or during the very stressful islet
isolation process, exposing islets to mechanical (shaking,
spinning) and enzymatic injury during the digestion phase.
The effectiveness of digestion is more related to the enzyme
quality, as well as donor age, which affects the extracellular
matrix composition including the type of collagen present,
rather than the size of the pancreas23. For that reason, young
donors (i.e., below 20 years of age) are not preferred due to
poor results of the digestion phase23.
NAIDS contains almost the same variables as the previ-
ous IDS; however, the number of points assigned for each
factor and the formula of the score calculation is different.
Fig. 3. Receiver operating characteristics (ROC) curves of the
NAIDS, modified IDS, and old IDS in the University of Chicago
validation cohort for the identification of islet isolation success
defined as total post-purification IEQ > 400,000.
Fig. 4. Receiver operating characteristics (ROC) curves of the
NAIDS in original derivation cohort (n ¼ 1056), original derivation
cohort (Edmonton) (n ¼ 179), and the University of Chicago vali-
dation cohort (n ¼ 82) for the identification of islet isolation suc-
cess defined as total post-purification IEQ > 400,000.
Table 6. University of Chicago Isolation Characteristics (n ¼ 82).
Mean + SD Range
Pre-purification
suspension total IEQ
391,534 + 195,932 41,701–1,204,503
Total post-purification
IEQ
322,500 + 172,827 16,202–808,633
Total infused IEQ* 464,340 + 119,717 269,228–686,988
Total tissue vol [ml] –
calculated*
5.67 + 2.35 2–10
Total purity* [%] 70.32 + 16.51 39–95
*data for 45 infused final islet preparations
** endotoxin level was < 5 Eu/kg in all cases
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Therefore, there may be a substantial difference in the dis-
tribution of results according to scoring model used; that is,
one donor could have been awarded a significantly lower
number of points in one of the scoring system as compared
with another, despite very similar donor data. AUROC was
higher for NAIDS than for IDS, although for our relatively
low number of cases the difference was not statistically sig-
nificant. Even though in our validation cohort the AUROC
for the identification of isolation success did not reach the
threshold of 0.70 typically considered useful for clinical
decision making, it still performed best out of the three scor-
ing systems. Still, there was a clean-cut trend when analyz-
ing the success rate based on various donor scores. We
noticed that when the NAIDS is below 50, the chance of
success was 0%, so it is not worth accepting and processing
the pancreas for islet isolation; however, we can still con-
sider isolating the islets when the score is between 50 and 80
as the chance of success is around 30%. With a score over 80
and the chance of success around 40%, we should proceed
with the islet isolation in our center. The rate of successful
isolations was similar irrespective of the scoring system used
whenever the sum of points exceeded 70. Our results indi-
cate that with the higher total number of points achieved,
either all scoring systems are equally useful or we were
unable to show the difference due to a small number of cases
included and a variety of factors affecting isolation out-
comes, which are not included in any of the scoring systems.
The main advantage in guiding clinical decisions using
NAIDS over IDS and modified IDS is that it was more
effective in identification of donors who would most likely
fail. So if we rejected pancreata based on donor IDS or
modified IDS, we would reject potentially good organs.
On the other hand, pancreas rejection based on NAIDS
improves the cost-effectiveness of isolation process, saving
time and valuable resources. In cases when the use of dif-
ferent scoring systems generates divergent results, NAIDS
better reflects the pancreas donor quality.
The critical message of our study is that NAIDS allows
assessment of the pancreas donor quality prior to processing,
not only in the most experienced center—Edmonton—but
also in smaller centers. We externally validated it. NAIDS
assists in making a difficult decision—whether to accept
donor and pancreas for processing or reject due to low
chance for success—easier. The cost of each islet isolation
is around $20,000 in the US, in addition to the cost of the
GMP facility maintenance and an on-call isolation team 24/
7. From the economic perspective, one can assume that it
would be optimal to wait for a perfect donor (NAIDS > 80)
in order to maximize the chance for successful isolation and
not to waste time and money on isolation failures. However,
such strategy may result in rare pancreas processing and
inefficiency due to high cost of the team and facility main-
tenance without productive work. Each islet center needs to
develop its own donor selection strategy and islet isolation
rate per month based on overall pancreas donor availability,
which depends on the local, regional, or national efficiency
of procurement. It also depends on activity of the pancreas
transplant programs, or competitive islet transplant centers.
Overall population BMI might be higher in the USA com-
pared with European countries, which can relatively increase
availability of higher NAIDS donors in the USA compared
with other countries. Between January 2013 and April 2015,
we participated in a multicenter trial with competitive enroll-
ment, so as a center we were continuously fully active, ready
to accept pancreata for processing. Over a 2-year period, we
performed 40 islet isolations with an overall success rate of
50% (20/40) with IEQ > 400,000, which resulted in clinical
transplants in our 12 patients. Among those, there were 13
(32.5%) donors with NAIDS  80, 19 (47.5%) with NAIDS
 60, and 8 (20%) below 60. The success rate was 62%,
50%, and 25%, respectively for the NAIDS groups. Taking
into consideration all the above factors, our previous expe-
rience, and data with different scoring systems, we decided
not to process pancreata with NAIDS below 60.
Of note, there was a substantial difference in the percent-
age of successful isolations between the Edmonton isolation
cohort and the University of Chicago isolation cohort when
donors were stratified according to NAIDS. The success of
the isolation depends on three main components: donor qual-
ity, pancreas procurement quality, and experience and effi-
ciency of the islet isolation team. NAIDS takes into
consideration only two of them: donor characteristic and
procurement team. Islet isolation is still a very complex
process and, despite standardization, decisions made based
on the experience of the leader of the isolation team play
very important role in the ultimate outcome. Poor decisions
may lead to failure despite processing a perfect pancreas.
The Edmonton group has the most experienced team and
islet isolation system based on thousands of isolations during
the last 20 years. For that reason, the results of processing the
same quality pancreas are overall better there than in our and
other centers. In addition, most pancreata are procured for us
by distant teams with different levels of experience in pan-
creas procurement. Very poor procurement with pancreas
injury, ischemia, poor perfusion, and inefficient organ cool-
ing or preservation may remain undetectable by the receiv-
ing islet center but severely compromise pancreas quality,
and may completely preclude success of islet isolation. This
most likely also affected our outcomes. Again, there is much
more experience with pancreas procurement in Edmonton
and Canada. Altogether, despite the substantial difference
in success rates in outcomes between our center and Edmon-
ton in respective ranges of scoring systems, NAIDS allowed
us to properly stratify the quality of the pancreas donor,
especially to identify poor-quality donors and to avoid many
isolation failures.
Several shortcomings of this study should be mentioned.
This was a small study restricted to a single center with
particular strategies for donor selection and islet isolation.
We believe that we could have demonstrated better efficacy
of NAIDS in an adequately powered study with a signifi-
cantly larger number of cases included. Data were collected
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prospectively and analyzed retrospectively with no actual
donor selection decisions based on only estimation of
NAIDS. Despite these limitations, we believe that our study
is of importance. This study is the first external validation
that assesses the performance of NAIDS in a population
external to and independent from the original derivation and
validation cohorts.
In conclusion, NAIDS allows for acceptable correlation
of the score with the outcome of the islet isolation. It allows
us to tailor donor selection strategy, excluding donors with
minimal chance for success with a score below 50 and accept
remaining pancreata with a chance of success of 30–40%.
Validation of NAIDS against data from our center shows that
it is currently the best available tool for donor pancreas
selection in clinical and research practice, allowing for
adjusting the donor selection strategy to the center’s logistic
and financial resources.
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